Outlook Therapeutics Stock (NASDAQ: OTLK)

Dernières nouvelles pour Outlook Therapeutics (NASDAQ:OTLK) Stock

OUTLOOK THERAPEUTICS INC

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

Westinghouse Air Brake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) has outperformed the market over the past 20 years by 7.76% on an annualized basis producing an average annual return of 15.93%. Currently, Westinghouse Air Brake has a market capitalization of $32.86 billion. 
Buying $100 In WAB: If an investor had bought $100 of WAB stock 20 years ago, it would be worth $1,923.27 today based on a price of $192.00 for WAB at the time of writing.
<h3>Westinghouse Air Brake's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746738917_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

BRT Apartments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRT#NYSE">BRT</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.27 by 44.44 percent. This is a 11.43 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $24.11 million which beat the analyst consensus estimate of $23.85 million by 1.07 percent. This is a 3.00 percent increase over sales of $23.40 million the same period last year.

Earnings

Earnings Beats

BRT Apartments Q1 FFO $0.39 Beats $0.27 Estimate, Sales $24.11M Beat $23.85M Estimate

Cantaloupe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.10 by 10 percent. This is a 50 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $75.43 million which missed the analyst consensus estimate of $79.83 million by 5.52 percent. This is a 11.09 percent increase over sales of $67.90 million the same period last year.

Earnings Misses

CTLP

Cantaloupe Q3 Adj. EPS $0.09 Misses $0.10 Estimate, Sales $75.43M Miss $79.83M Estimate

Chartwell Retirement (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CSH#TSX">CSH</a>) reported quarterly earnings of $0.20 per share. This is a 25 percent increase over earnings of $0.16 per share from the same period last year. The company reported $243.57 million in sales this quarter. This is a 32.43 percent increase over sales of $183.92 million the same period last year.

TSX:CSH

Chartwell Retirement Q1 FFO $0.20 Up From $0.16 YoY, Sales $243.57M Up From $183.92M YoY

Oculis Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.43) by 60.47 percent. This is a 56.82 percent decrease over losses of $(0.44) per share from the same period last year.

Oculis Holding Q1 EPS $(0.69) Misses $(0.43) Estimate

Lassonde Industries (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LAS#TSX">LAS</a>) reported quarterly earnings of $4.00 per share which beat the analyst consensus estimate of $2.97 by 34.68 percent. This is a 8.7 percent increase over earnings of $3.68 per share from the same period last year. The company reported quarterly sales of $699.70 million which beat the analyst consensus estimate of $669.28 million by 4.55 percent. This is a 22.80 percent increase over sales of $569.80 million the same period last year.

TSX:LAS

TSX:LAS.A

Lassonde Industries Q1 Adj. EPS $4.00 Beats $2.97 Estimate, Sales $699.70M Beat $669.28M Estimate

QXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 percent. This is a 114.29 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $13.51 million which beat the analyst consensus estimate of $12.00 million by 12.57 percent. This is a 6.43 percent decrease over sales of $14.44 million the same period last year.

QXO Q1 EPS $(0.03) Beats $(0.05) Estimate, Sales $13.51M Beat $12.00M Estimate

Post Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $1.20 by 17.5 percent. This is a 6.62 percent decrease over earnings of $1.51 per share from the same period last year. The company reported quarterly sales of $1.95 billion which missed the analyst consensus estimate of $1.98 billion by 1.32 percent. This is a 2.35 percent decrease over sales of $2.00 billion the same period last year.

POST

Post Hldgs Q2 Adj. EPS $1.41 Beats $1.20 Estimate, Sales $1.95B Miss $1.98B Estimate

Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that it entered into a private placement transaction (the "Private Placement") for US$6.0 million in gross proceeds, from the sale of 1,200,000 of the Company's Class A common shares (the "Shares") for US$5.00 per Share.
The Shares are being sold to certain non-U.S. purchasers (the "Purchasers") in a transaction exempt from registration under the Securities Act of 1933, as amended, in reliance on Regulation S thereunder. Each of the Purchasers understands that the Shares have not been registered under the Securities Act and such Purchasers may not sell or otherwise dispose of the Shares without registration under the Securities Act and under applicable state securities or "Blue Sky" laws, or pursuant to an exemption therefrom. Closing of the Private Placement is subject to customary closing conditions.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Offerings

DOGZ

Dogness  Announces That It Has Entered Into A Private Placement Transaction For $6M In Gross Proceeds From the Sale Of 1.2M Shares Of The Company's Class A Common Shares For $5.00 Per Share

BRDG

Bridge Investment Group Q1 Distributable EPS $0.09 Misses $0.16 Estimate

Definity Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DFY#TSX">DFY</a>) reported quarterly earnings of $0.65 per share which missed the analyst consensus estimate of $0.75 by 13.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.11 billion which beat the analyst consensus estimate of $1.07 billion by 3.93 percent. This is a 12.11 percent increase over sales of $991.90 million the same period last year.

TSX:DFY

Definity Financial Q1 Adj. EPS $0.65 Misses $0.75 Estimate, Sales $1.11B Beat $1.07B Estimate

ISBA

Isabella Bank To Be Listed On Nasdaq Under "ISBA" On May 12, 2025

Marygold Companies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MGLD#AMEX">MGLD</a>) reported quarterly losses of $(0.02) per share. This is a 100 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $7.03 million in sales this quarter. This is a 10.82 percent decrease over sales of $7.88 million the same period last year.

The Marygold Companies, Inc. Common Stock

MGLD

Marygold Companies Q3 EPS $(0.02) Down From $(0.01) YoY, Sales $7.03M Down From $7.88M YoY

WIIM

VEEE

VEEE stock has given up its prior loss. Twin Vee PowerCats shares were trading lower after the company announced a proposed offering of common stock. The company also reported Q1 financial results

Dividends

NHC Increases Dividend From $0.61 To $0.64

Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) lowers FY2025 sales outlook from $107.00 million-$122.00 million to $104.00 million-$115.00 million vs $112.08 million estimate.

Guidance

VERI

Veritone Lowers FY2025 Sales Guidance from $107.00M-$122.00M to $104.00M-$115.00M vs $112.08M Est

Logan Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRFC#NASDAQ">LRFC</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.37 by 5.41 percent. This is unchanged from the same period last year. The company reported quarterly sales of $4.63 million which missed the analyst consensus estimate of $5.20 million by 10.94 percent. This is a 7.44 percent decrease over sales of $5.00 million the same period last year.

LRFC

Logan Ridge Finance Q1 Net Investment Income per share of $0.35 Misses $0.37 Estimate, Total investment income $4.63M

Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) sees Q2 sales of $23.000 million-$25.000 million vs $28.23 million analyst estimate.

Veritone Sees Q2 Sales $23.000M-$25.000M vs $28.23M Est

Fair Isaac Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) announced today that it priced $1.5 billion in aggregate principal amount of 6.000% Senior Notes due 2033 (the "Notes") in a private offering that is exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"). The Notes were priced to investors at 100% of their principal amount and are senior unsecured obligations of FICO.
FICO intends to use the net proceeds from the offering of the Notes to repay certain indebtedness outstanding under its existing unsecured revolving credit facility and unsecured term loans, to pay related fees and expenses, and for general corporate purposes.
FICO expects to close on the sale of the Notes on May 13, 2025, subject to customary closing conditions.

FICO

Fair Isaac Announces It Priced $1.5B In Aggregate Principal Amount Of 6.000% Senior Notes Due 2033

ESAB

ESAB Announces Quarterly Dividend Increase From $0.08/Shr To $0.10/Shr

Press Releases

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Comments

Outlook Therapeutics

Actualités

Dernières nouvelles pour Outlook Therapeutics (NASDAQ:OTLK) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL